» Articles » PMID: 28503546

Computational Tool for Fast Evaluation of ERG K Channel Affinity

Overview
Journal Front Chem
Specialty Chemistry
Date 2017 May 16
PMID 28503546
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

The development of a novel comprehensive approach for the prediction of ERG activity is herein presented. Software Phase has been used to derive a 3D-QSAR model, employing as alignment rule a common pharmacophore built on a subset of 22 highly active compounds (threshold : 50 nM) against ERG K channel. Five features comprised the pharmacophore: two aromatic rings (R and R), one hydrogen-bond acceptor (A), one hydrophobic site (H), and one positive ionizable function (P). The sequential 3D-QSAR model developed with a set of 421 compounds (randomly divided in training and test set) yielded a test set () = 0.802 and proved to be predictive with respect to an external test set of 309 compounds that were not used to generate the model ([Formula: see text] = 0.860). Furthermore, the model was submitted to an validation for assessing the reliability of the approach, by applying a decoys set, evaluating the Güner and Henry score () and the Enrichment Factor (), and by using the ROC curve analysis. The outcome demonstrated the high predictive power of the inclusive 3D-QSAR model developed for the ERG K channel blockers, confirming the fundamental validity of the chosen approach for obtaining a fast proprietary cardiotoxicity predictive tool to be employed for rationally designing compounds with reduced ERG K channel activity at the early steps of the drug discovery trajectory.

Citing Articles

Identification of Novel Drug Molecules Against NS3-Like Helicase Enzyme of Alongshan Virus.

Gul F, Ahmad S, Khan K, Masood R, Siddique F, Bibi M Mol Biotechnol. 2024; .

PMID: 39643757 DOI: 10.1007/s12033-024-01326-z.


Synthesis and Evaluation of Thiazolyl-indole-2-carboxamide Derivatives as Potent Multitarget Anticancer Agents.

Saadan N, Ahmed W, Kadi A, Al-Mutairi M, Al-Wabli R, Rahman A ACS Omega. 2024; 9(40):41944-41967.

PMID: 39398118 PMC: 11465279. DOI: 10.1021/acsomega.4c06889.


Lead optimisation of OXS007417: PK profile and hERG liability modulation to optimise a small molecule differentiation agent for the potential treatment of acute myeloid leukaemia.

Cogswell T, Josa-Cullere L, Zimmer D, Galan S, Jay-Smith M, Harris K RSC Med Chem. 2024; .

PMID: 39220761 PMC: 11361297. DOI: 10.1039/d4md00275j.


Enhancing hERG Risk Assessment with Interpretable Classificatory and Regression Models.

Sanches I, Braga R, Alves V, Andrade C Chem Res Toxicol. 2024; 37(6):910-922.

PMID: 38781421 PMC: 11187631. DOI: 10.1021/acs.chemrestox.3c00400.


Using the Correlation Intensity Index to Build a Model of Cardiotoxicity of Piperidine Derivatives.

Toropova A, Toropov A, Roncaglioni A, Benfenati E Molecules. 2023; 28(18).

PMID: 37764363 PMC: 10535953. DOI: 10.3390/molecules28186587.


References
1.
Rajamani S, Eckhardt L, Valdivia C, Klemens C, Gillman B, Anderson C . Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol. 2006; 149(5):481-9. PMC: 2014667. DOI: 10.1038/sj.bjp.0706892. View

2.
De Bruin M, Pettersson M, Meyboom R, Hoes A, Leufkens H . Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J. 2005; 26(6):590-7. DOI: 10.1093/eurheartj/ehi092. View

3.
Brindisi M, Butini S, Franceschini S, Brogi S, Trotta F, Ros S . Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies. J Med Chem. 2014; 57(22):9578-97. DOI: 10.1021/jm501119j. View

4.
Sanguinetti M, Tristani-Firouzi M . hERG potassium channels and cardiac arrhythmia. Nature. 2006; 440(7083):463-9. DOI: 10.1038/nature04710. View

5.
Thomas D, Kathofer S, Zhang W, Wu K, Wimmer A, Zitron E . Acute effects of dronedarone on both components of the cardiac delayed rectifier K+ current, HERG and KvLQT1/minK potassium channels. Br J Pharmacol. 2003; 140(5):996-1002. PMC: 1574095. DOI: 10.1038/sj.bjp.0705502. View